Moustafa Gabr

Associate Professor at Weill Cornell Medicine. Medicinal Chemistry 💊, Chemical Biology 🧬🧫, Molecular Imaging🔬, and Translational Research💉👨‍⚕️ 🇪🇬

[Moustafa Gabr @MT_Gabr]

Excited to share that I will be joining @WeillCornell as an assistant professor. The Gabr lab will open its doors in January at the Molecular Imaging Innovations Institute @WCMRadiology
We will use chemical biology and med chem to develop small molecule-based immunotheranostics

[Columbia Radiology @columbiaimaging]

We're thrilled to announce that Moustafa Gabr, PhD, (@MT_Gabr), will join @columbiaimaging on July 1st as Director of Molecular Imaging and Therapeutics Research! #Theranostics #MolecularImaging #TeamScience #MolRad
https://t.co/KU2lWp2NuX

[RCNS MedChem Research Group @keserulab]

In a fantastic collaboration with the group of @MT_Gabr, we have contributed to the discovery of a submicromolar agonist of TREM2, a new-generation Alzheimer's disease target. Read more in @ACSMedChemLett: https://t.co/n6fCpjik7T

[Waggoner Lab @LabWaggoner]

Designing immunity with cytokines: A logic-based framework for programmable CAR therapies
https://t.co/eu3K9kiZgt @MT_Gabr @WeillCornell

[Biology+AI Daily @BiologyAIDaily]

HTS-Oracle: A Retrainable AI Platform for High-Confidence Hit Identification Across Difficult-to-Drug Targets

1. The introduction of HTS-Oracle marks a significant advancement in high-throughput screening (HTS) for drug discovery. This AI platform leverages deep learning to integrate molecular embeddings from ChemBERTa with traditional cheminformatics features, offering a powerful ensemble framework for predicting high-confidence hits across challenging targets.

2. One of the key innovations of HTS-Oracle is its ability to reprioritize and streamline the screening process. By enriching true positives and filtering out non-binders upfront, it significantly reduces the experimental burden and improves the efficiency of hit identification, particularly for difficult-to-drug targets like the immune co-stimulatory receptor CD28.

3. The platform demonstrated an impressive 8.4% hit rate in prospective screening, representing an eightfold improvement over conventional methods such as surface plasmon resonance (SPR) and affinity selection mass spectrometry (ASMS). This highlights HTS-Oracle’s potential to transform early-stage drug discovery by prioritizing high-confidence hits from large compound libraries.

4. HTS-Oracle’s architecture is designed for retrainability and adaptability. It can be retrained for new targets, making it a scalable and practical tool for iterative library refinement and target-specific optimization. This flexibility is crucial for addressing the diverse challenges in drug discovery across different therapeutic areas.

5. The study also validated the platform’s predictions experimentally, identifying two compounds that disrupted the CD28–B7.1 interaction with micromolar potency. These findings underscore the platform’s ability to identify novel small molecule inhibitors, even for targets historically considered intractable.

6. HTS-Oracle is released as an open-source platform, complete with training code and a pre-trained model. This accessibility encourages broader adoption and further development within the scientific community, providing a strong foundation for integrating AI into prospective screening workflows.

📜Paper: https://t.co/l81Ymfr5gH
💻Code: https://t.co/8KiGlHxbzE
#HTSOracle #AIDrugDiscovery #HighThroughputScreening #MachineLearning #DrugDiscovery #OpenSource #AIPlatform

[Weill Cornell Medicine Radiology @WCMRadiology]

🏥 Read "Virtual screening: hope, hype, and the fine line in between" by Hossam Nada, Nicholas Meanwell, & @MT_Gabr in 'Expert Opinion on Drug Discovery' 👉 https://t.co/pKrm2S837O

[Moustafa Gabr @MT_Gabr]

Excellent opportunity to join the Faltas lab

[Dr. Bishoy M. Faltas @FaltasLab]

Please retweet! We are looking for outstanding postdocs interested in studying cancer evolution!
🌟 See our recent work https://t.co/eKNtUHhjwt

🔬 Research Areas:
1️⃣ APOBEC3 induced mutations & RNA editing in cancer evolution.
2️⃣ Extrachromosomal DNA & therapy resistance.
3️⃣ Role of the noncoding genome in cancer evolution.
4️⃣ Bio-Digital Avatars for personalized therapy.
5️⃣ Translational cancer drug development.

Details: https://t.co/405QxiQ4UW

#PostDocPosition #CancerResearch #NYCJobs #科研 #博士后招聘 #生命科学 #研究職 #ポスドク募集 #ライフサイエンス #연구직 #포닥모집

[Dr. Bishoy M. Faltas @FaltasLab]

Our new paper published today in @Nature! Study Uncovers Mutations and DNA Structures Driving Bladder Cancer https://t.co/3uQpQ1Bc34

[Weill Cornell Medicine Radiology @WCMRadiology]

📝 Read "Discovery of ICOS-targeted small molecules using affinity selection mass spectrometry screening," a @biorxivpreprint by Longfei Zhang, Laura Calvo-Barreiro, @MT_Gabr, & co. 👉 https://t.co/pApvHRFNxK

[Moustafa Gabr @MT_Gabr]

🚨Job alert🚨Thrilled to share that the Gabr Lab received FIVE R01 grants for small molecule immunomodulators research. We are hiring postdocs with expertise in medicinal chemistry, neuropharmacology, or protein biochemistry. Applicants can send CVs to [email protected]

[Moustafa Gabr @MT_Gabr]

Happy to see our recent publication in ACS Medicinal Chemistry Letters highlighted on the journal cover!

Details on this novel class of TIM-3-targeted peptides as immunomodulators can be found here:
https://t.co/hGoQOOEPej

[Weill Cornell Medicine Radiology @WCMRadiology]

🏥 Read "Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors," recent work from Somaya Abdel-Rahman & @MT_Gabr in @ACSMedChemLett, a publication of @AmerChemSociety, here 👉 https://t.co/kWZcZ5sBjN

[Moustafa Gabr @MT_Gabr]

Glad to share that our paper on small molecule LAG-3 inhibitors has been selected for a special collection on the Future of Medicinal Chemistry. We’re proud to be the first to target LAG-3 with small molecules and thankful to the Elsa U. Pardee Foundation for their support

[Mohammed AlQuraishi @MoAlQuraishi]

Introducing Genie 2, our latest protein design model! Genie 2 sets a new state of the art on key design metrics and supports motif scaffolding, including that of multiple motifs with undefined geometric relationships, a feature new to protein diffusion models. (1/5)

[Moustafa Gabr @MT_Gabr]

@FaltasLab @NatureComms @WCMGUcancer @WeillCornell @ElementoLab @WCMEnglanderIPM @WCMCPathology @PGrivasMDPhD @BladderCancerUS @montypal @neerajaiims @DrScottTagawa @KentaroOhara3 @DrChoueiri @afrendeiro @Kyrillus2 Congrats Bishoy!

[RSC Advances @RSCAdvances]

The Gabr Lab at Weill Cornell reports 3-oxo-lithocholic acid amidates as potent modulators of the nuclear receptor RORγt @MT_Gabr

https://t.co/tiiclzVdji

[Weill Cornell Medicine Radiology @WCMRadiology]

📝In 'Bioorganic & Medicinal Chemistry Letters,' the work of S. Abdel-Rahman, L. Calvo-Barreiro, & @MT_Gabr lays the groundwork for future #cancer drug discovery endeavors, with the goal of developing cyclic peptides targeting the ICOS/ICOSL interaction. https://t.co/tpRQzxgHZY

[JPM_MDPI @JPM_MDPI]

📢Read our Newly_Published_Paper
"This comprehensive review explores cutting-edge developments in targeting immune #checkpoints, focusing on both #small_molecule- and #peptide-based approaches."

👨‍💻By Moustafa Gabr @MT_Gabr et al.
🏫@WeillCornell
📚More: https://t.co/TwK4pdZEv1

[Weill Cornell Medicine Radiology @WCMRadiology]

🧠 In @ACSChemNeurosci, a publication of @AmerChemSociety, @MT_Gabr reports new quinolinone hybrids as dual inhibitors of acetylcholinesterase (AChE) and Aβ aggregation, functioning as multitargeted ligands for Alzheimer's disease. https://t.co/1eCYq6oRsj

[Md Kausar Raza, PhD @Kausar_Chem]

Delighted to contribute to this remarkable project! Heartiest congratulations to @ShoaibM15096060 & team @jmiu_official & fantastic collaborator @MT_Gabr from @WeillCornell 4 bringing this work to fruition after a dedicated 6-year journey! @ACSPublications @ACSChemNeurosci

[ChemMedChem @ChemMedChem]

Discovery of ICOS-Targeted Small Molecules Using Pharmacophore-Based Screening (M. T. Gabr et al.) @MT_Gabr https://t.co/uPAkFjyEVy